reports
restor3d Completes Acquisition of Conformis
restor3d Completes Acquisition of Conformis Combination Creates the World’s Preeminent Producer of Personalized Orthopedic Medical Devices, with Unmatched Additive Manufacturing Capabilities DURHAM, North Carolina and BILLERICA, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- restor3d, Inc. and Conformis, Inc. announced today that restor3d has completed its previously announced acquisition of Conformis following the approval of Conformis’ stockholders at a special meeting held on August 31, 2023. In connection with the completion of the acquisition, shares of Conformis’ common stock ceased tr...
Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Conform...
Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Conformis Stockholders Vote “FOR” the Pending Merger with restor3d BILLERICA, Mass., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:), a leading medical technology company featuring personalized knee and hip replacement products, announced today that leading independent proxy advisory firms, Institutional Shareholder Services Inc. (“ISS”) and Glass Lewis & Co., LLC (“Glass Lewis”), have each recommended that Conformis stockholders vote “FOR” the pending merger transaction with restor3d. As previously announced, und...
Independent Proxy Advisory Firm ISS Recommends Conformis Stockholders ...
Independent Proxy Advisory Firm ISS Recommends Conformis Stockholders Vote “FOR” the Pending Merger with restor3d BILLERICA, Mass., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:), a leading medical technology company featuring personalized knee and hip replacement products, announced today that leading independent proxy advisory firm, Institutional Shareholder Services Inc. (“ISS”), has recommended that Conformis stockholders vote “FOR” the pending merger transaction with restor3d. As previously announced, under the terms of the definitive merger agreement, restor3d will a...
Conformis Reports Second Quarter 2023 Financial Results
Conformis Reports Second Quarter 2023 Financial Results BILLERICA, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), an orthopedic medical device company that features personalized knee and hip replacement products, announced today financial results for the second quarter ended June 30, 2023. Second Quarter 2023 Summary Total revenue of $13.0 million, a decrease of 15% year-over-year on a reported and constant currency basis.Product revenue of $12.5 million, a decrease of 17% year-over-year on a reported and constant currency basis.Conformis hip system revenue ...
Conformis Announces Definitive Agreement to be Acquired by restor3d fo...
Conformis Announces Definitive Agreement to be Acquired by restor3d for a Purchase Price of $2.27 Per Share in Cash Combination creates a leading personalized 3D-printed orthopedic medical device company DURHAM, N.C. and BILLERICA, Mass., June 22, 2023 (GLOBE NEWSWIRE) -- restor3d, Inc. and Conformis, Inc. (NASDAQ: CFMS) announced today that they have entered into a definitive merger agreement under which restor3d, a leading personalized 3D-printed orthopedic company, will acquire all outstanding shares of common stock of Conformis at $2.27 per share in cash, which represents an approxi...
Conformis Reports First Quarter 2023 Financial Results
Conformis Reports First Quarter 2023 Financial Results BILLERICA, Mass., May 08, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), an orthopedic medical device company that features personalized knee and hip replacement products, announced today financial results for the first quarter ended March 31, 2023. First Quarter 2023 Summary Total revenue of $12.8 million, a decrease of 17% year-over-year on a reported and constant currency basis.Product revenue of $12.7 million, a decrease of 15% year-over-year on a reported basis and 14% on a constant currency basis.Conformis hip sys...
Conformis, Inc. to Announce Financial Results for Its First Quarter on...
Conformis, Inc. to Announce Financial Results for Its First Quarter on May 8, 2023 BILLERICA, Mass., April 13, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ: CFMS), a leading medical device company that features personalized knee and hip replacement products, announced today it will release its financial results for the first quarter ended March 31, 2023, before the market opens on Monday, May 8, 2023. Mark Augusti, CEO, and Bob Howe, CFO, will host a webcast and conference call at 8:30 a.m. Eastern Time to discuss the financial results and provide a business update. Earnings Call an...
Conformis Launches Patient Awareness Campaign to Highlight the Benefit...
Conformis Launches Patient Awareness Campaign to Highlight the Benefits of Personalized Knee Replacement Procedures The campaign underscores that patients have a choice of implant when undergoing total knee arthroscopy, and that they should advocate for the many benefits of a fully personalized knee BILLERICA, Mass., March 21, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:), a leading medical technology company featuring personalized knee and hip replacement products, recently launched a patient education and awareness campaign in selected U.S. markets to strengthen the importance of...
Conformis, Inc. Reports Fourth Quarter and Year End 2022 Financial Res...
Conformis, Inc. Reports Fourth Quarter and Year End 2022 Financial Results BILLERICA, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) an orthopedic medical device company that features personalized knee and hip replacement products, announced today financial results for the fourth quarter and year ended December 31, 2022. Fourth Quarter 2022 Summary Total revenue of $17.4 million, an increase of 13% year-over-year on a reported basis and 14% on a constant currency basis.Product revenue of $14.2 million, a decrease of 7% year-over-year on a reported basis and 6% o...
Conformis, Inc. to Participate in Upcoming Investor Conferences
Conformis, Inc. to Participate in Upcoming Investor Conferences BILLERICA, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), an orthopedic medical device company that features personalized knee and hip replacement products, announced today that Mark Augusti, Chief Executive Officer, and Bob Howe, Chief Financial Officer, will participate at two upcoming investor conferences. March 8 – 43rd Annual Cowen Healthcare Conference The 43rd Annual Cowen Healthcare Conference will take place at the Boston Marriott Copley Place from March 6-8, 2023. Conformis management...
Conformis, Inc., Bodycad Laboratories, Inc. and Bodycad USA Corp. Anno...
Conformis, Inc., Bodycad Laboratories, Inc. and Bodycad USA Corp. Announce Settlement of Patent Litigation Conformis and Bodycad Settle Litigation Related to Bodycad’s Patient-Specific Instruments and Implants BILLERICA, Mass., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) along with Bodycad Laboratories, Inc. and Bodycad USA Corp. announced today that they have entered into a settlement and license agreement that resolves the patent infringement dispute filed by Conformis in June of 2021. Conformis and Bodycad are pleased to have resolved their ongoing patent litigat...
Conformis Provides Business Update and Reports Preliminary Results for...
Conformis Provides Business Update and Reports Preliminary Results for Fourth Quarter and Full-Year 2022 Company Launches New Advertising Campaign BILLERICA, Mass., Feb. 10, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), an orthopedic medical device company that features personalized knee and hip replacement products, provided today a business update and reported preliminary financial results for the fourth quarter and year ended December 31, 2022. Executive Commentary – Mark Augusti, President and CEO “Today we are announcing the launch of our new advertising campaign highli...
Conformis, Inc. to Announce Financial Results for Its Fourth Quarter a...
Conformis, Inc. to Announce Financial Results for Its Fourth Quarter and Full-Year 2022 BILLERICA, Mass., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ: CFMS), a leading medical device company that features personalized knee and hip replacement products, announced today it will release its financial results for the fourth quarter and full-year ended December 31, 2022, after the market closes on Wednesday, March 1, 2023. Mark Augusti, CEO, and Bob Howe, CFO, will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the financial results and provide a busines...
Conformis, Inc. Regains Compliance with Nasdaq’s Minimum Bid Price Rul...
Conformis, Inc. Regains Compliance with Nasdaq’s Minimum Bid Price Rule BILLERICA, Mass., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today that it received a letter from the Listing Qualifications Department of The NASDAQ Stock Market (“NASDAQ”) on November 25, 2022 notifying Conformis that, based on the closing bid price of Conformis’ common stock having been $1.00 per share or greater on each of the trading days from November 10, 2022 to November 23, 2022, Conformis has regained compliance with Nasdaq Listing Rule 5550(a)(2) and the minimum bid price defic...
Conformis Announces First Procedure Performed Using New Actera™ Hip Sy...
Conformis Announces First Procedure Performed Using New Actera™ Hip System First Actera™ procedure underscores company’s ongoing commitment to advancing joint replacement technology by leveraging its data-driven approach and surgical planning expertise BILLERICA, Mass., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), a leading medical device company that features personalized knee and hip replacement products, today announced that the first procedure with the company’s new Actera™ Hip System has been performed. Dr. William Kurtz, MD performed the hip replacement proc...
Conformis Announces Full Commercial Launch of Imprint™
Conformis Announces Full Commercial Launch of Imprint™ Conformis’ Imprint™ knee system introduces the new “Made-to-Measure” product category option for Total Knee Arthroplasty (TKA) BILLERICA, Mass., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), a leading medical technology company featuring personalized knee and hip replacement products, today announced the full commercial launch of its new Imprint™ knee system. This launch marks the formal transition to its new U.S. business model where the made-to-measure Imprint™ system is now the Conformis’ primary knee offering,...
Conformis, Inc. Announces Settlement of Medacta Patent Litigation
Conformis, Inc. Announces Settlement of Medacta Patent Litigation Conformis Settles Medacta Litigation Related to Patient-Specific Instruments BILLERICA, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today that it has entered into a settlement and license agreement with Medacta USA, Medacta Germany GmbH, and Medacta International SA (together, “Medacta”) that resolves all patent disputes between the companies. “We are pleased to have resolved all of the ongoing patent litigation related to the Medacta dispute,” said Mark Augusti, President and Chief...
Conformis, Inc. Effects 1-for-25 Reverse Stock Split
Conformis, Inc. Effects 1-for-25 Reverse Stock Split BILLERICA, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) (“Conformis”) announced that it will effect a 1-for-25 reverse stock split at 5:00 p.m. Eastern time today. Beginning with the opening of trading on November 10, 2022, Conformis’ common stock will trade on the Nasdaq Capital Market on a split-adjusted basis under a new CUSIP number 20717E200. At Conformis’ Special Meeting of Stockholders on October 26, 2022, Conformis’ stockholders approved the proposal to authorize Conformis’ Board of Directors to file a...
Conformis Reports Third Quarter 2022 Financial Results
Conformis Reports Third Quarter 2022 Financial Results BILLERICA, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), an orthopedic medical device company that features personalized knee and hip replacement products, announced today financial results for the third quarter ended September 30, 2022. Third Quarter 2022 Summary Total revenue of $13.8 million, a decrease of 3% year-over-year on a reported basis and 2% on a constant currency basis.Product revenue of $13.6 million, a decrease of 3% year-over-year on a reported basis and 2% on a constant currency basis.Confo...
Conformis, Inc. to Announce Financial Results for Its Third Quarter 20...
Conformis, Inc. to Announce Financial Results for Its Third Quarter 2022 BILLERICA, Mass., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ: CFMS), a leading medical device company that features personalized knee and hip replacement products, announced today it will release its financial results for the third quarter ended September 30, 2022, after the market closes on Wednesday, November 2, 2022. Mark Augusti, CEO, and Bob Howe, CFO, will host a webcast and conference call later that day at 4:30 p.m. Eastern Time to discuss the financial results and provide a business update. ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.